Amarin Corporation
biopharmaceutical company
AMRN Nasdaq
ISIN US0231114044 SEC CIK 897448
Follow Amarin
Weekly email: filings, results
Revenue, last quarter
$39.6M
−20.4% vs same quarter last year
Net income
$245K
+103.2% vs same quarter last year
EPS, diluted
$0.00
+100% vs same quarter last year
Operating cash flow
$9.2M
+172.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $213.6M | −$38.8M |
| FY24 | $228.6M | −$87M |
| FY23 | $306.9M | −$55M |
| FY22 | $369.2M | −$105.8M |
| FY21 | $583.2M | $7.7M |
| FY20 | $614.1M | −$18M |
| FY19 | $429.8M | −$22.6M |
| FY18 | $229.2M | −$116.4M |
| FY17 | $181.1M | −$67.9M |
| FY16 | $130.1M | −$86.4M |
| FY15 | $81.8M | −$115.2M |
| FY14 | $54.2M | −$56.4M |
| FY13 | $26.4M | −$166.2M |
| FY12 | - | −$179.2M |
| FY11 | - | −$69.1M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 56.6% | −23.5% | −18.2% |
| FY24 | 35.6% | −40.2% | −38.1% |
| FY23 | 53.9% | −22% | −17.9% |
| FY22 | 65.7% | −28.7% | −28.7% |
| FY21 | 79.2% | 1.8% | 1.3% |
| FY20 | 78.6% | −3.2% | −2.9% |
| FY19 | 77.7% | −5.6% | −5.3% |
| FY18 | 76.2% | −47.2% | −50.8% |
| FY17 | 75.2% | −25.2% | −37.5% |
| FY16 | 73.6% | −50.4% | −66.4% |
| FY15 | 65.9% | −120.1% | −140.9% |
| FY14 | 62.2% | −177% | −104% |
| FY13 | 54.8% | −691.1% | −630.8% |
| FY12 | - | - | - |
| FY11 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | −$22M |
| FY19 | −$11.8M |
| FY18 | −$94.8M |
| FY17 | −$32.8M |
| FY16 | −$71.8M |
| FY15 | −$84M |
| FY14 | - |
| FY13 | −$190.4M |
| FY12 | −$122.9M |
| FY11 | −$39.8M |
- Amarin
- Healthcare median
Show the numbers
| Year | Amarin | Healthcare median |
|---|---|---|
| FY25 | −18.2% | −30.6% |
| FY24 | −38.1% | −47% |
| FY23 | −17.9% | −58% |
| FY22 | −28.7% | −80.4% |
| FY21 | 1.3% | −71.8% |
| FY20 | −2.9% | −62.2% |
| FY19 | −5.3% | −46.2% |
| FY18 | −50.8% | −49.6% |
| FY17 | −37.5% | −45.9% |
| FY16 | −66.4% | −36% |
| FY15 | −140.9% | −37.8% |
| FY14 | −104% | −35.5% |
| FY13 | −630.8% | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |